Pharmaron Acquires Quotient Bioresearch
To enhance service offerings and increase presence in global markets
BEIJING, February 4, 2016 – Pharmaron, a fully integrated contract research
organization (CRO) offering laboratory and manufacturing services for pharmaceutical
and biotech research and development, today announced that it acquired Quotient
Bioresearch (Quotient). Quotient, a UK-based CRO with more than 200 employees,
focuses on integrating radiochemistry and metabolism. Part of this expertise is derived
from Quotient’s previous acquisition of GE Amersham’s radiosynthesis business.
Integrated with Pharmaron’s broader technology platforms in chemistry, biology, DMPK,
pharmacology, safety assessment, chemical and pharmaceutical development, this
acquisition strengthens the company’s service portfolio, allowing it to provide more
comprehensive and integrated services. The addition of the radiochemistry capabilities
creates a global leading chemistry platform with a full spectrum of services. Further, the
combined entity will generate greater market access in Asia, Europe and the United
States.
“We are very pleased to have Quotient Bioresearch join the Pharmaron team.” said Dr.
Boliang Lou, Chairman and Chief Executive Officer of Pharmaron. “This acquisition is
part of our long-term strategy to grow our services and broaden our technical and
geographic footprint to better serve clients throughout the world. Combining these two
companies gives Pharmaron industry-leading custom radiosynthesis capabilities, and
further consolidates our leading position in the field of discovery, pre-clinical and clinical
DMPK. This move will help accelerate the discovery and development of novel drugs for
our customers with Pharmaron’s comprehensive and integrated drug research and
development engine.”
Stephen Lewinton, Managing Director of Quotient, said, “Quotient is focused on
radiosynthesis and regulatory DMPK, particularly human clinical metabolism while
Pharmaron has premier expertise in drug R&D services including discovery and preclinical safety and early phase DMPK. We are excited to become part of Pharmaron’s
integrated drug research and development platform.”
Teneo Capital served as financial advisor to Pharmaron in the transaction and
O’Melveny & Meyers LLP served as Pharmaron’s legal advisor.
About Pharmaron
Pharmaron is a private, premier R&D service provider for the life science industry.
Founded in 2003, Pharmaron has invested in its people and facilities, and established a
broad spectrum of drug R&D service capabilities, ranging from synthetic and medicinal
chemistry, biology, DMPK, pharmacology and safety assessment to chemical &
pharmaceutical development. With over 3,000 employees and operations in China and
the U.S., Pharmaron has an excellent track record in the delivery of R&D solutions to its
partners in North America, Europe, Japan and China. For more information, please visit:
www.pharmaron.com
About Quotient
Quotient Bioresearch is a leading UK CRO based in Cardiff and Northampton, providing
Radiochemistry, Drug Metabolism and E-fate solutions tailored, integrated and delivered
to pharmaceutical, biotechnology, agrochemical and chemical sponsors worldwide,
using state-of-the-art technologies underpinned by unparalleled scientific, chemical and
biological expertise. The Cardiff site derived from the acquisition of Amersham custom
radiolabeling business from GE Healthcare.
Amersham, the premier radiosynthesis
laboratories in the world, was founded in 1940. The Northampton site derived from the
acquisition of BioDynamics, a specialist DMPK CRO founded in early 90s. For more
information, please visit:
www.quotientbioresearch.com
Contact
Ashok Tehim, Ph.D.
Senior Vice President of Strategy
ashok.tehim@pharmaron.com
(201) 312-5754